Health - Jun 17
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
wire - news in brief
Category
Results 201 - 250 of 325.
European Commission approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Approval based on significant survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (N
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche commences tender offer for all shares of Spark Therapeutics, Inc. for US$ 114.50 per share in cash Roche today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of Spark Therapeutics, Inc.
Roche submits supplemental new drug application to FDA for Venclexta plus Gazyva for previously untreated chronic lymphocytic leukaemia with co-existing medical conditions
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
Application is being reviewed under FDA's Real-Time Oncology Review pilot programme Combination was granted Breakthrough Therapy Designation, the fifth for Venclexta Roche today announced the submiss
A look into the future
What could the "gas station of the future" look like? What services does it offer? Which fuels can be filled up there and where do they come from? The Swiss Oil Industry Association (Erdöl-Vereinigun
What could the "gas station of the future" look like? What services does it offer? Which fuels can be filled up there and where do they come from? The Swiss Oil Industry Association (Erdöl-Vereinigun
Judit Leinert, you're a specialist in good decision making. How can I decide on the perfect place to go on holiday this summer? In my research group, we approach decision making with the help of "Multi-Criteria Decision Analysis", or MCDA.
Novartis Cosentyx shows superior improvements in psoriasis patients’ quality of life versus Janssen’s IL-23 Stelara *
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
New CLARITY data show over two-thirds of Cosentyx (secukinumab) treated patients with moderate to severe psoriasis reported no impact of skin disease on their quality of life (QoL) up to Week 16 compared to Stelara * (68.4% versus 55.9%, respectively) Results from CLARITY study presented in 2018 showed Cosentyx was significantly more effective than Stelara * in delivering clear and almost clear skin at 12 and 16 weeks.
"Ticino's economic complexity", the seventh report published by the USI Observatory for Economic Dynamics (O-De, Institute for Economic Research), shows high values in terms of the economic competitiveness of the Canton Ticino.
The European Commission has chosen Time Machine as one of the six proposals retained for preparing large scale research initiatives to be strategically developed in the next decade.
FDA approves Herceptin Hylecta for subcutaneous injection in certain HER2-positive breast cancers
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Roche today announced that the US Food and Drug Administration (FDA) has approved Herceptin Hylecta? (trastuzumab and hyaluronidase-oysk) for subcutaneous (under the skin) injection for the treatment
Children are her passion
At the Paul Scherrer Institute PSI, Beate Timmermann built up a programme providing proton therapy for children with cancer at the same time she was raising her own son.
At the Paul Scherrer Institute PSI, Beate Timmermann built up a programme providing proton therapy for children with cancer at the same time she was raising her own son.
Alpine streams have been extensively modified by dams and water intakes to permit hydropower exploitation. This leads to changes in flow regimes and sediment dynamics, and thus also in the distribution of animal and plant species. To keep ecological impacts to a minimum, it is important to ensure adequate minimum flows and, in addition, to restore natural sediment dynamics.
A new method shows that the relationships between living species, from bacteria to plants and animals, are different from previous estimates.
Precision medicine "tailored" to individual patients is regarded as the medicine of the future. It is already being practiced at the University of Bern and Inselspital, Bern University Hospital.
DFAB HOUSE has officially opened today on the NEST building of Empa and Eawag in Dübendorf. It is the world's first inhabited "house" that was not only digitally planned, but also ' with the help of robots and 3D printers ' built largely digitally. The construction technologies were developed by ETH Zurich researchers in collaboration with industrial partners.
Committed to Sustainable Plant Production for the Reduction of Pesticides
Vegetables and fruits are an essential part of a healthy diet - but it is these foods in particular which usually require an above-average use of plant-protection products (PPPs).
Vegetables and fruits are an essential part of a healthy diet - but it is these foods in particular which usually require an above-average use of plant-protection products (PPPs).
Roche enters into definitive merger agreement to acquire Spark Therapeutics
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
Roche to acquire Spark Therapeutics for US$ 114.50 per share Spark Therapeutics is a leader in discovering, developing and delivering gene therapies with one commercial asset and four programm
As part of a strategic international cooperation program of the Fraunhofer-Gesellschaft, Empa in Dübendorf (CH) and the Fraunhofer Institute for Silicate Research ISC in Würzburg (D) launched a three
Portable sensors that prevent injuries to skin and tissue should allow a patient to lie for an extended period of time: With this project, researchers from Empa and the University of Bern were successful in the current call for proposals for BRIDGE funding from the SNF and Innosuisse.
The solar panels developed by startup Insolight boast an impressive 29% yield - a record for the retail market. These systems, which have now been standardized for mass production, contain lenses that focus sunlight on tiny high-yield photovoltaic cells, employing what is a pioneering approach for the solar-power industry.
As the world's population continues to grow, the piles of biowaste also tower higher and higher.
FDA grants priority review to Roche’s polatuzumab vedotin in previously treated aggressive lymphoma
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
Diffuse large B-cell lymphoma is an aggressive type of blood cancer that typically becomes harder to treat each time it returns Polatuzumab vedotin has shown significant potential to improve outcomes
FDA grants Priority Review to Roche’s personalised medicine entrectinib
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
Roche today announced that the US Food and Drug Administration (FDA) has accepted the company's New Drug Applications (NDAs) and granted Priority Review for entrectinib for the treatment of adult and
The Gambia, Guinea Bissau, Mauritania and Senegal initiate a discussion for the joint management of a shared aquifer system essential to the economic and socialdevelopment of this region of 24 million people.
Together with BRUAG Fire Protection AG, Empa specialists have developed a new flame retardant for wood and wood-based materials.
Together with BRUAG Fire Protection AG, Empa specialists have developed a new flame retardant for wood and wood-based materials.
Health - Jun 17
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
New analysis of Novartis data confirms that Cosentyx demonstrates durable comprehensive treatment across psoriatic disease
Health - Jun 14
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy
New Sandoz biosimilar adalimumab data confirms switching from reference biologic has no impact on safety or efficacy